Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Teriflunomide
Drug ID BADD_D02165
Description Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Indications and Usage Used in the treatment of relapsing forms of multiple sclerosis (MS).
Marketing Status Prescription
ATC Code L04AA31
DrugBank ID DB08880
KEGG ID D10172
MeSH ID C527525
PubChem ID 54684141
TTD Drug ID Not Available
NDC Product Code 69238-1303; 65727-058; 12579-186; 69238-1304; 66499-0059; 59285-001; 69539-032; 47621-049; 17337-0070; 69037-0016; 58468-0211; 63850-8081; 12579-185; 46708-888; 12579-191; 53747-061; 69539-033; 14501-0086; 58468-0210; 59651-036; 66039-916; 0115-1565; 12579-190
Synonyms teriflunomide | (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | (2Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide | RS 61980 | Aubagio | HMR1726 | HMR-1726 | A 771726 | A 1726 | A771726 | A-771726 | A77 1726
Chemical Information
Molecular Formula C12H9F3N2O2
CAS Registry Number 163451-81-8
SMILES CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Carpal tunnel syndrome17.09.02.0010.002316%Not Available
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Cerebral atrophy17.11.01.0010.001158%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.004--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cervical dysplasia21.06.01.0020.002316%Not Available
Cervicobrachial syndrome17.10.02.001; 15.01.04.0020.001158%Not Available
Cervix carcinoma16.12.01.001; 21.06.02.0010.003474%Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.023160%Not Available
Chills15.05.03.016; 08.01.09.0010.009264%
Cholecystitis09.03.01.0010.005790%
Cholecystitis acute09.03.01.0030.001158%Not Available
Cholelithiasis09.03.01.0020.008685%Not Available
Cholestasis09.01.01.001--Not Available
Chromaturia20.02.01.0020.004053%
Chronic lymphocytic leukaemia01.10.06.001; 16.01.06.0010.000453%Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.0040.001737%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.001737%Not Available
Colitis07.08.01.0010.010422%
Colitis ulcerative07.08.01.005; 10.02.01.0040.005790%Not Available
Colon cancer07.21.01.001; 16.13.01.001--Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctival haemorrhage24.07.05.001; 06.07.01.0010.001158%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.001158%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 26 Pages